Nitrosamines in Pharmaceuticals: What are your options as October 1, 2020 approaches?
IPA is pleased to organize this virtual complimentary live presentation with case studies sponsored by Neopharm Labs. Risk assessments for genotoxic impurities have been performed in the pharmaceutical industry for many years. However, after finding nitrosamine impurities in Valsartan drug products in 2018, these specific impurities became a subject of concern for health authorities (FDA, […]